Find out how to deal online from £1.50 in a SIPP, ISA or Dealing Account.
Jump to:

Oncimmune Holdings Fundamentals

Company Name Oncimmune Holdings Last Updated 21 Aug 2019
Industry Health Care Sector Biotechnology
Shares in Issue (m) 63.25 Market Cap (£m) 56.29
PE Ratio -7.80 Div per Share () 0.00
Div Yield 0.00 Div Cover 0.00
EPS -11.41 EPS Growth (%) -15.96
PEG 0.49 DPS Growth (%) n/a
Debt Ratio 0.00 Debt Equity Ratio 0.00
Net Gearing -83.99 Gross Gearing 5.89
Asset Equity Ratio 1.06 Cash Equity Ratio 95.51
Quick Ratio 15.60 Current Ratio 15.95
Price To Book Value 4.15 ROCE -46.76

Oncimmune Holdings Dividends

Type Ex-Date Pay Date Currency Net Dividend Year Total

Oncimmune Holdings Company Financials

Assets (£m) 2018 2017 2016
Tangible Assets 0 0 0
Intangible Assets 1 1 0
Investments 0 0 0
Total Fixed Assets 1 1 0
Stocks 0 0 0
Debtors 0 0 0
Cash & Equivalents 13 5 10
Other Assets 0 0 0
Total Assets 14 6 11
Liabilities (£m) 2018 2017 2016
Creditors within 1 year 1 1 1
Creditors after 1 year 0 0 0
Other Liabilities 0 0 0
Total Liabilities 1 1 1
Net assets 14 5 10
Equity (£m) 2018 2017 2016
Called up share capital 1 1 1
Share Premium 31 16 16
Profit / Loss -6 -5 -9
Other Equity 31 31 31
Preference & Minorities 0 0 0
Total Capital Employed 14 5 10
Ratios 2018 2017 2016
Debt Ratio 0.00 0.00 3.90
Debt-to-Equity 0.00 0.00 0.27
Net Gearing -83.99 -57.31 -77.80
Gross Gearing 5.89 21.90 13.18
Assets / Equity 1.06 1.28 1.15
Cash / Equity 95.51 101.42 104.79
EPS -11.41 -9.84 -23.54
Cash Flow (£m) 2018 2017 2016
Cash from operating activities -6 -4 -3
Cashflow before financing -6 -5 -3
Increase in Cash 8 -5 9
Income (£m) 2018 2017 2016
Turnover 0 0 0
Cost of sales 1 1 0
Gross Profit -1 -0 0
Operating Profit -6 -5 -6
Pre-Tax profit -6 -5 -9
Profit / Loss for the year 1 1 1

Oncimmune Holdings Company Background

Sector Biotechnology
Activities Oncimmune Holdings plc is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT tests for liver and ovarian cancer are in development.
Latest Interim Date 13 Feb 2019
Latest Fiscal Year End Date 31 Oct 2018

Oncimmune Holdings Directors

Appointed Director Position
09 Apr 2018 Dr Adam Mark Hill Chief Executive Officer
06 Dec 2018 Frank Matthew Sunderland Hall Chief Financial Officer
01 Jul 2007 Geoffrey Neil Hamilton-Fairley Executive Vice Chairman
26 Nov 2015 Meinhard Folkert Schmidt Non-Executive Chairman
26 Nov 2015 Timothy Brian Bunting Non-Executive Dep Chairman
26 Nov 2015 Andrew Vaughan Unitt Non-Executive Director
26 Nov 2015 Richard Simon Sharp Non-Executive Director
11 Oct 2016 Carsten Schroeder Non-Executive Director
09 Jan 2018 Dr Annalisa Mary Jenkins Non-Executive Director
23 Jun 2016 Julian Clement Hirst Non-Executive Director
28 Sep 2018 Dr Cheung To Non-Executive Director

Oncimmune Holdings Contact Details

Company Name Oncimmune Holdings
Company Address Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB.
Company Telephone +44 (0)115 8231869
Company Website http://www.oncimmune.co.uk/

Oncimmune Holdings Advisors

Auditor Name Grant Thornton UK LLP
Auditor Address Byron House, Cambridge Business Park, Cowley Road, Cambridge CB4 0WZ.
Auditor Website http://www.grant-thornton.co.uk/
Auditor Telephone +44 (0)1223 225 600
Registrar Name Capita Registrars
Registrar Address The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
Registrar Website http://www.capitaregistrars.com/
Registrar Telephone 0870 162 3100
Broker Name Zeus Capital
Broker Address 3 Ralli Courts, West Riverside, Manchester M3 5FT.
Broker Website http://www.zeuscapital.co.uk/
Broker Telephone +44 (0)161 831 1512
Adviser Name Zeus Capital
Adviser Address 3 Ralli Courts, West Riverside, Manchester M3 5FT.
Adviser Website http://www.zeuscapital.co.uk/
Adviser Telephone +44 (0)161 831 1512
Solicitor Name Preachey & Co
Solicitor Address 95 Aldwych, London, WC2B 4JF
Solicitor Website http://www.peachey.co.uk/
Solicitor Telephone +44 (0)20 7316 522
Stockbroker Name n/a
Stockbroker Address n/a
Stockbroker Website n/a
Stockbroker Telephone n/a